29.08.2022 • NewsNovartisSandozgenerics

Novartis Definitely Plans to Spin off Sandoz

Novartis has finally confirmed definite plans to spin off its generic drugs arm Sandoz.

It gave no timetable for the move which had seemed a foregone conclusion even before the Swiss drugmaker in October 2021 announced it was conducting a strategic review for the underperforming subsidiary.

During the review period, the Basel-based group said the generics side of its portfolio continued to be trapped in a protracted downward price spiral, reinforcing the need to separate the two segments and allow Novartis to focus on its more profitable prescription drugs business.

Sandoz, which generated nearly $10 billion in sales last year from generics and biosimilars, will emerge as Europe's leading generics company, Novartis predicted.

Despite the currently sagging numbers, Novartis CEO Vas Narasimhan said the market for generics is "highly attractive,”as branded products worth $400-500 billon are likely to go off-patent over the coming decade.

After the spinoff, Narasimhan said Sandoz would still be headquartered in Switzerland. The company’s shares would be listed on the SIX Swiss Exchange, with an American Depositary Receipt program in the US. Richard Saynor would stay on board as CEO.

In a conference call, Narasimhan told analysts that, apart part from some preliminary interest, the company had received no formal binding offers for Sandoz. If these were to materialize, management would “fully consider“ them. However, he said, “we think a spin is by far and away the most likely and best way to separate these two companies.”

Some analysts seemed less certain. At Citi, the view was that competitive pressures in the generic space a likely to translate into lesser near-term stock market interest.

Author: Dede Williams, Freelance Journalist

© Novartis
© Novartis

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.